• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丙型肝炎患者经干扰素治疗获得持续病毒学应答29年后发生肝细胞癌:一例报告

Hepatocellular Carcinoma Developing in a Patient 29 Years After Achieving Sustained Virologic Response for Hepatitis C With Interferon Therapy: A Case Report.

作者信息

Maezawa Yosuke, Kodama Yukiko, Ariga Hiroyuki, Kashimura Junya, Irie Toshiyuki

机构信息

Department of Internal Medicine, Mito Kyodo General Hospital, Mito, JPN.

Department of Gastroenterology, Mito Kyodo General Hospital, Mito, JPN.

出版信息

Cureus. 2024 Nov 23;16(11):e74330. doi: 10.7759/cureus.74330. eCollection 2024 Nov.

DOI:10.7759/cureus.74330
PMID:39720368
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11667130/
Abstract

We report a case of an 87-year-old female with a ruptured hepatocellular carcinoma (HCC). She presented with sudden epigastric and right upper abdominal pain. The physical examination revealed mild tenderness in the right upper abdomen, a positive Murphy's sign, and no jaundice. Laboratory tests showed mild anemia and elevated PIVKA-II (prothrombin induced by vitamin K absence II) levels. Abdominal ultrasound and CT revealed a large hypervascular mass in the liver, along with ascites and portal vein thrombosis. The patient had received interferon therapy for hepatitis C virus (HCV) 29 years before her presentation and blood tests and imaging examinations had confirmed sustained undetectability for HCV ribonucleic acid (RNA) and the absence of HCC for five years following treatment. HCV RNA remained undetectable at the time of her admission, and it was presumed that it had been negative for 29 years post-treatment, with no evidence of re-exposure. The patient had not attended any follow-up appointments. While there have been no reported cases of a patient developing HCC 29 years after achieving sustained virologic response (SVR), our case suggests that the absence of HCC risk is not guaranteed, even after a prolonged period post-SVR. Therefore, periodic imaging tests such as abdominal ultrasound or CT may be beneficial in detecting potential HCC, even long after achieving SVR.

摘要

我们报告一例87岁女性肝细胞癌(HCC)破裂病例。她因突发上腹部和右上腹疼痛就诊。体格检查发现右上腹轻度压痛、墨菲氏征阳性,无黄疸。实验室检查显示轻度贫血及异常凝血酶原(PIVKA-II)水平升高。腹部超声和CT检查发现肝脏有一个大的高血运肿块,伴有腹水和门静脉血栓形成。该患者在此次就诊前29年曾接受丙型肝炎病毒(HCV)干扰素治疗,血液检查和影像学检查证实治疗后HCV核糖核酸(RNA)持续检测不到且5年未发生HCC。入院时HCV RNA仍检测不到,推测治疗后29年一直呈阴性,且无再次感染证据。该患者未进行任何随访。虽然尚无关于患者在获得持续病毒学应答(SVR)29年后发生HCC的报道,但我们的病例提示,即使在SVR后很长时间,也不能保证没有HCC风险。因此,即使在实现SVR很长时间后,定期进行腹部超声或CT等影像学检查可能有助于发现潜在的HCC。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a1/11667130/64f9fbb32872/cureus-0016-00000074330-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a1/11667130/5df1dae1970e/cureus-0016-00000074330-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a1/11667130/2c23f9ae6a58/cureus-0016-00000074330-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a1/11667130/64f9fbb32872/cureus-0016-00000074330-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a1/11667130/5df1dae1970e/cureus-0016-00000074330-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a1/11667130/2c23f9ae6a58/cureus-0016-00000074330-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a1/11667130/64f9fbb32872/cureus-0016-00000074330-i03.jpg

相似文献

1
Hepatocellular Carcinoma Developing in a Patient 29 Years After Achieving Sustained Virologic Response for Hepatitis C With Interferon Therapy: A Case Report.丙型肝炎患者经干扰素治疗获得持续病毒学应答29年后发生肝细胞癌:一例报告
Cureus. 2024 Nov 23;16(11):e74330. doi: 10.7759/cureus.74330. eCollection 2024 Nov.
2
Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.直接作用抗病毒药物治疗后成功的丙型肝炎病毒复发,随后发生肝细胞癌肉瘤样改变:一例报告。
J Med Case Rep. 2020 May 27;14(1):62. doi: 10.1186/s13256-020-02392-y.
3
Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.非酒精性脂肪性肝病是慢性丙型肝炎患者持续病毒学应答后发生肝细胞癌的危险因素:一项前瞻性四年随访研究。
Metabol Open. 2021 Mar 26;10:100090. doi: 10.1016/j.metop.2021.100090. eCollection 2021 Jun.
4
Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.在日本,接受无干扰素治疗与基于干扰素治疗并实现持续病毒学应答的慢性丙型肝炎患者的背景特征差异,以及丙型肝炎病毒根除后发生肝细胞癌的风险。
J Viral Hepat. 2017 Jun;24(6):472-476. doi: 10.1111/jvh.12665. Epub 2017 Jan 11.
5
Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection.钆塞酸二钠增强 MRI 上治疗前非富血供低信号结节作为 HCV 感染持续病毒学应答后肝细胞癌发展的预测因子。
Aliment Pharmacol Ther. 2021 Jun;53(12):1309-1316. doi: 10.1111/apt.16382. Epub 2021 Apr 25.
6
Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.细胞因子动力学可预测慢性丙型肝炎病毒感染者病毒清除后发生肝细胞癌的风险。
World J Gastroenterol. 2022 Jan 7;28(1):140-153. doi: 10.3748/wjg.v28.i1.140.
7
Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.加拿大丙型肝炎患者持续病毒学应答对肝细胞癌的长期影响。
J Hepatol. 2017 Mar;66(3):504-513. doi: 10.1016/j.jhep.2016.10.028. Epub 2016 Nov 4.
8
Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.慢性丙型肝炎病毒感染获得持续病毒学应答的非肝硬化患者发生肝细胞癌的危险因素。
J Gastroenterol Hepatol. 2015 Jul;30(7):1183-9. doi: 10.1111/jgh.12915.
9
Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.丙型肝炎病毒感染和高级纤维化患者治疗后持续病毒学应答的肝细胞癌监测的成本效益。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1840-1849.e16. doi: 10.1016/j.cgh.2018.12.018. Epub 2018 Dec 20.
10
Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response.动态评估肝纤维化以评估慢性丙型肝炎患者获得持续病毒学应答后发生肝细胞癌的风险。
Clin Infect Dis. 2020 Mar 3;70(6):1208-1214. doi: 10.1093/cid/ciz359.

本文引用的文献

1
Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis.肝硬化慢性丙型肝炎病毒感染患者队列中的肝细胞癌监测。
J Gastrointest Cancer. 2020 Jun;51(2):461-468. doi: 10.1007/s12029-019-00255-4.
2
Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response.在实现持续病毒学应答的丙型肝炎病毒感染患者中,肝细胞癌的发病率和危险因素随时间而变化。
Hepatol Res. 2019 May;49(5):570-578. doi: 10.1111/hepr.13310. Epub 2019 Feb 6.
3
Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
丙型肝炎抗病毒治疗后肝细胞癌风险预测模型的建立。
J Hepatol. 2018 Nov;69(5):1088-1098. doi: 10.1016/j.jhep.2018.07.024. Epub 2018 Aug 21.
4
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.直接作用抗病毒 HCV 治疗后肝细胞癌风险:系统评价、荟萃分析和荟萃回归。
J Hepatol. 2017 Dec;67(6):1204-1212. doi: 10.1016/j.jhep.2017.07.025. Epub 2017 Aug 9.
5
Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy.基于干扰素的抗病毒治疗抑制丙型肝炎患者肝癌的发展。
Hepatol Res. 2015 Jan;45(2):152-61. doi: 10.1111/hepr.12393. Epub 2014 Oct 14.
6
Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes.慢性丙型肝炎患者实现干扰素持续病毒学应答后的肝癌发生:为改善结局而进行终身定期癌症筛查的意义。
J Gastroenterol. 2014 Nov;49(11):1504-13. doi: 10.1007/s00535-013-0921-z. Epub 2013 Dec 8.
7
New horizons in hepatitis C antiviral therapy with direct-acting antivirals.直接作用抗病毒药物在丙型肝炎抗病毒治疗中的新进展。
Hepatology. 2013 Jul;58(1):428-38. doi: 10.1002/hep.26371. Epub 2013 May 31.
8
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.2 型糖尿病对恶性肿瘤风险的影响包括慢性丙型肝炎中的肝细胞癌。
Hepatology. 2013 Mar;57(3):964-73. doi: 10.1002/hep.26087. Epub 2013 Feb 7.
9
Epidemiology of viral hepatitis and hepatocellular carcinoma.病毒性肝炎与肝细胞癌的流行病学。
Gastroenterology. 2012 May;142(6):1264-1273.e1. doi: 10.1053/j.gastro.2011.12.061.
10
Surveillance for hepatocellular carcinoma: in whom and how?肝细胞癌的监测:对象及方式?
Therap Adv Gastroenterol. 2011 Jan;4(1):5-10. doi: 10.1177/1756283X10385964.